Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. At the heart of everything we do is our commitment to patients and their families. They inspire us to go beyond incremental progress to develop transformative therapies born from thoughtful science that leads to meaningful changes in their lives. Our initial focus is developing tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of mucopolysaccharidoses type (MPS or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies.